Effects of intracoronary infusion of the vasoactive intestinal peptide antagonist [4Cl-D-Phe 6-Leu 17]VIP in the awake dog

Intracoronary infusion of [4Cl-D-Phe 6-Leu 17]VIP caused modest significant inhibition of the coronary vasodilation produced by intraarterial VIP, but did not significantly inhibit serotonin-induced coronary vasodilation. In addition, infusion of [4Cl-D-Phe 6-Leu 17]VIP did not result in significant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Peptides (New York, N.Y. : 1980) N.Y. : 1980), 1991-09, Vol.12 (5), p.989-993
Hauptverfasser:	Quebbemann, Brian B., Rivier, Jean, Bache, Robert J.
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Hydroxytryptamine Animals Antianginal agents. Coronary vasodilator agents Biological and medical sciences Blood Pressure - drug effects Cardiovascular system Coronary circulation Coronary Circulation - drug effects Coronary Vessels - drug effects Coronary Vessels - physiology Dogs Female Heart Rate - drug effects Infusions, Intra-Arterial Male Medical sciences Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - physiology Pharmacology. Drug treatments Reference Values Serotonin - administration & dosage Serotonin - pharmacology Vasoactive Intestinal Peptide - administration & dosage Vasoactive Intestinal Peptide - analogs & derivatives Vasoactive Intestinal Peptide - antagonists & inhibitors Vasoactive Intestinal Peptide - pharmacology Vasoactive intestinal peptide antagonist Vasodilation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Intracoronary infusion of [4Cl-D-Phe 6-Leu 17]VIP caused modest significant inhibition of the coronary vasodilation produced by intraarterial VIP, but did not significantly inhibit serotonin-induced coronary vasodilation. In addition, infusion of [4Cl-D-Phe 6-Leu 17]VIP did not result in significant changes in baseline coronary resistance, heart rate or left ventricular dP/dt. These findings demonstrate that [4Cl-D-Phe 6-Leu 17]VIP is a competitive antagonist of VIP-induced vasodilation in the canine coronary circulation, but fail to demonstrate a significant role for VIP in the regulation of resting coronary vasomotor tone, and do not support the hypothesis that VIP is a mediator of serotonin-induced coronary arteriolar dilation.
ISSN:	0196-9781 1873-5169
DOI:	10.1016/0196-9781(91)90048-T